https://narraj.org/main/issue/feed Narra J 2022-08-01T00:00:00+07:00 Harapan Harapan, MD, DTM&H, PhD harapan@unsyiah.ac.id Open Journal Systems <div id="groups"> <div id="groups"> <div class="group"> <h2>Editor in Chief</h2> <div class="editorial-list"> <ul class="list-unstyled"> <li> <div class="img-profile"> <div class="imgthumb"><img src="https://narraj.org/public/site/images/narradmin/harapan.jpg" alt="Profile Image" width="75" height="100" /></div> </div> <div class="team-content"> <div class="team-aff"> <ul class="list-unstyled"> <li><strong>Harapan Harapan, MD., PhD</strong></li> <li>Medical Research Unit, School of Medicine</li> <li>Universitas Syiah Kuala, Indonesia</li> <li>Scopus ID : <a title="Scopus ID" href="https://www.scopus.com/authid/detail.uri?authorId=55844857500" target="_blank" rel="noopener" data-toggle="tooltip">55844857500</a></li> </ul> </div> </div> </li> </ul> </div> </div> <div class="group"> <h2>Co-Editor in Chief</h2> <div class="editorial-list"> <ul class="list-unstyled"> <li> <div class="img-profile"> <div class="imgthumb"><img src="https://narraj.org/public/site/images/narradmin/kuldeep-dhama.jpg" alt="Profile Image" width="75" height="100" /></div> </div> <div class="team-content"> <div class="team-aff"> <ul class="list-unstyled"> <li><strong>Kuldeep Dhama, MVSc., PhD</strong></li> <li>NAAS Associate, Principal Scientist</li> <li>ICAR-Indian Veterinary Research Institute, India</li> <li>Scopus ID : <a title="Scopus ID" href="https://www.scopus.com/authid/detail.uri?authorId=6507396956" target="_blank" rel="noopener" data-toggle="tooltip">6507396956</a></li> <li>Email : <a href="https://narraj.org/main/management/settings/context#masthead/kdhama@rediffmail.com">kdhama@rediffmail.com</a></li> </ul> </div> </div> </li> <li> <div class="img-profile"> <div class="imgthumb"><img src="https://narraj.org/public/site/images/narradmin/abram-l-wagner.jpg" alt="Profile Image" width="75" height="100" /></div> </div> <div class="team-content"> <div class="team-aff"> <ul class="list-unstyled"> <li><strong>Abram L. Wagner, PhD, MPH</strong></li> <li>School of Public Health</li> <li>University of Michigan</li> <li>Scopus ID : <a title="Scopus ID" href="https://www.scopus.com/authid/detail.uri?authorId=56178049300" target="_blank" rel="noopener" data-toggle="tooltip">56178049300</a></li> <li>Email : <a href="https://narraj.org/main/management/settings/context#masthead/awag@umich.edu">awag@umich.edu</a></li> </ul> </div> </div> </li> </ul> </div> </div> <div class="group"> <h2>Editorial Board</h2> <div class="editorial-list"> <ul class="list-unstyled"> <li> <div class="img-profile"> <div class="imgthumb"><img src="https://narraj.org/public/site/images/narradmin/ruth-müller.png" alt="Profile Image" width="75" height="100" /></div> </div> <div class="team-content"> <div class="team-aff"> <ul class="list-unstyled"> <li><strong>Ruth Müller, PhD</strong></li> <li>Department of Biomedical Sciences</li> <li>Institute of Tropical Medicine, Belgium</li> <li>Scopus ID : <a title="Scopus ID" href="https://www.scopus.com/authid/detail.uri?authorId=25653255200" target="_blank" rel="noopener" data-toggle="tooltip">25653255200</a></li> <li>Email : <a href="https://narraj.org/main/management/settings/context#masthead/mailto:rmuller@itg.be">rmuller@itg.be</a></li> </ul> </div> </div> </li> <li> <div class="img-profile"> <div class="imgthumb"><img src="https://narraj.org/public/site/images/narradmin/mahir-gachabayov.jpeg" alt="Profile Image" width="75" height="100" /></div> </div> <div class="team-content"> <div class="team-aff"> <ul class="list-unstyled"> <li><strong>Mahir Gachabayov, MD., PhD</strong></li> <li>School of Medicine</li> <li>New York Medical College, USA</li> <li>Scopus ID : <a title="Scopus ID" href="https://www.scopus.com/authid/detail.uri?authorId=56626010400" target="_blank" rel="noopener" data-toggle="tooltip">56626010400</a></li> <li>Email : <a href="https://narraj.org/main/management/settings/context#masthead/gachabayovmahir@gmail.com">gachabayovmahir@gmail.com</a></li> </ul> </div> </div> </li> <li> <div class="img-profile"> <div class="imgthumb"><img src="https://narraj.org/public/site/images/narradmin/morteza-arab.jpg" alt="Profile Image" width="75" height="100" /></div> </div> <div class="team-content"> <div class="team-aff"> <ul class="list-unstyled"> <li><strong>Morteza Arab-Zozani, PhD</strong></li> <li>School of Public Health</li> <li>Birjand University of Medical Sciences (BUMS), Iran</li> <li>Scopus ID : <a title="Scopus ID" href="https://www.scopus.com/authid/detail.uri?authorId=57210284593" target="_blank" rel="noopener" data-toggle="tooltip">57210284593</a></li> <li>Email : <a href="https://narraj.org/main/management/settings/context#masthead/arab.hta@gmail.com">arab.hta@gmail.com</a></li> </ul> </div> </div> </li> <li> <div class="img-profile"> <div class="imgthumb"><img src="https://narraj.org/public/site/images/narradmin/talha-bin-emran.jpg" alt="Profile Image" width="75" height="100" /></div> </div> <div class="team-content"> <div class="team-aff"> <ul class="list-unstyled"> <li><strong>Talha Bin Emran, PhD</strong></li> <li>Department of Pharmacy</li> <li>BGC Trust University Bangladesh, Bangladesh</li> <li>Scopus ID : <a title="Scopus ID" href="https://www.scopus.com/authid/detail.uri?authorId=55325267100" target="_blank" rel="noopener" data-toggle="tooltip">55325267100</a></li> <li>Email : <a href="https://narraj.org/main/management/settings/context#masthead/talhabmb@bgctub.ac.bd">talhabmb@bgctub.ac.bd</a></li> </ul> </div> </div> </li> <li> <div class="img-profile"> <div class="imgthumb"><img src="https://narraj.org/public/site/images/narradmin/dina-nur-anggraini-ningrum.png" alt="Profile Image" width="75" height="100" /></div> </div> <div class="team-content"> <div class="team-aff"> <ul class="list-unstyled"> <li><strong>Dina Nur Anggraini Ningrum, PhD</strong></li> <li>Department of Public Health</li> <li>Universitas Negeri Semarang, Indonesia</li> <li>Scopus ID : <a title="Scopus ID" href="https://www.scopus.com/authid/detail.uri?authorId=57195329470" target="_blank" rel="noopener" data-toggle="tooltip">57195329470</a></li> <li>Email : <a href="https://narraj.org/main/management/settings/context#masthead/dinanan@mail.unnes.ac.id">dinanan@mail.unnes.ac.id</a></li> </ul> </div> </div> </li> <li> <div class="img-profile"> <div class="imgthumb"><img src="https://narraj.org/public/site/images/narradmin/arief-budi-witarto.png" alt="Profile Image" width="75" height="100" /></div> </div> <div class="team-content"> <div class="team-aff"> <ul class="list-unstyled"> <li><strong>Arief Budi Witarto, PhD</strong></li> <li>Department of Biochemistry and Molecular Biology</li> <li>Indonesian Defense University, Indonesia</li> <li>Scopus ID : <a title="Scopus ID" href="https://www.scopus.com/authid/detail.uri?authorId=6507004235" target="_blank" rel="noopener" data-toggle="tooltip">6507004235</a></li> <li>Email : <a href="https://narraj.org/main/management/settings/context#masthead/arief.witarto@idu.ac.id">arief.witarto@idu.ac.id</a></li> </ul> </div> </div> </li> </ul> </div> </div> <div class="group"> <h2>Managing Editor</h2> <div class="editorial-list"> <ul class="list-unstyled"> <li> <div class="img-profile"> <div class="imgthumb"><img src="https://narraj.org/public/site/images/narradmin/henry-surendra.png" alt="Profile Image" width="75" height="100" /></div> </div> <div class="team-content"> <div class="team-aff"> <ul class="list-unstyled"> <li><strong>Henry Surendra, PhD</strong></li> <li>Eijkman-Oxford Clinical Research Unit, Indonesia</li> </ul> </div> </div> </li> <li> <div class="img-profile"> <div class="imgthumb"><img src="https://narraj.org/public/site/images/narradmin/muhammad-iqhrammullah.jpg" alt="Profile Image" width="75" height="100" /></div> </div> <div class="team-content"> <div class="team-aff"> <ul class="list-unstyled"> <li><strong>Muhammad Iqhrammullah, M.S</strong></li> <li>Universitas Syiah Kuala, Indonesia</li> </ul> </div> </div> </li> <li> <div class="img-profile"> <div class="imgthumb"><img src="https://narraj.org/public/site/images/narradmin/baidillah-zulkifli.png" alt="Profile Image" width="75" height="100" /></div> </div> <div class="team-content"> <div class="team-aff"> <ul class="list-unstyled"> <li><strong>Baidillah Zulkifli, M.VetMed</strong></li> <li>Universitas Syiah Kuala, Indonesia</li> </ul> </div> </div> </li> </ul> </div> </div> </div> </div> https://narraj.org/main/article/view/81 Giant bronchopleural fistula and empyema in a tuberculosis patient with diabetes mellitus: Vista from a high tuberculosis burden country in Southeast Asia 2022-05-10T06:41:02+07:00 Budi Yanti yantipulmonologis@gmail.com Saiful Hadi saifulhadiatjeh@gmail.com Fenny Harrika bintang_611@yahoo.com Aamir Shehzad wildlifepk1947@gmail.com <div> <div> <p class="NAbstractNEW"><span lang="EN-US">Bronchopleural fistula is a pathological tract between the bronchial tree and the pleural space, which can be life-threatening due to tension pneumothorax. It is a rare complication in tuberculosis cases with highly variable in clinical manifestations and persistent air leaks which might lead to complications such as empyema. Herein, we present a tuberculosis and diabetic patient complicated with giant bronchopleural fistula and empyema. A 48-year-old man presented with shortness of breath for two weeks and cough with phlegm for two months. The patient was a smoker with severe Brinkman Index and diabetes. Physical examination revealed hyper resonant percussion and vesicular diminished on the left hemithorax. Laboratory results indicated the patient had anemia, leukocytosis, and hypoalbuminemia. GeneXpert sputum confirmed the presence of <em>Mycobacterium tuberculosis</em> and chest X-ray indicated a collapsed left lung. The patient was diagnosed with left secondary spontaneous pneumothorax, pulmonary tuberculosis, and diabetes. The patient was treated with chest tube drainage and anti-tuberculosis drugs. There was no improvement based on serial chest X-ray, and empyema appeared from the chest tube. CT-scan showed tuberculosis lesion, the collapsed of the left lung and fistula in segments 7-8 inferior lobe. Exploratory thoracostomy was performed, in which a giant bronchopleural fistula was detected and then repaired with BioGlue surgical adhesive. Unfortunately, the thoracostomy led to extensive subcutaneous emphysema and was treated by cervical mediastinotomy. The drainage was unable to be removed, and the patient was discharged with Heimlich-type drainage valves on day 28 of treatment. The empyema fluid was cultured and revealed <em>Staphylococcus haemolyticus</em>. This case highlights that tuberculosis could cause a bronchopleural fistula and empyema may occur secondary to late diagnosis that needs immediate surgery. </span></p> </div> </div> 2022-08-01T00:00:00+07:00 Copyright (c) 2022 Budi Yanti, Saiful Hadi, Fenny Harrika, Aamir Shehzad https://narraj.org/main/article/view/82 Human albumin solution utilization patterns prior and during COVID-19 pandemic in United Arab Emirates: Time to develop and implement national guideline on prescribing and utilization 2022-07-17T17:03:55+07:00 Mohammed Sallam mediclinic.research@gmail.com Johan Snygg johan.snygg@mediclinic.ae <p>The human albumin solution (HAS) has limited but important indications in clinical practice. However, the inappropriate use of HAS can be costly. Thus, it is imperative to establish a practical protocol to use albumin products and rationalize its usage. The aim of this study was to identify albumin utilization patterns in a multi-specialty private hospital in Dubai, United Arab Emirates (UAE), before and during the COVID-19 epidemic in the country. In addition, the objectives were to demonstrate the importance of reconsidering the prescribing strategies for albumin administration. All data on 20% HAS administration in Mediclinic Welcare Hospital were retrieved during January 2019–May 2021, including the total quantities administered and data on primary diagnosis. A total of 579 patient admissions with several diagnoses were included in the study. The percentage of clinically indicated 20% HAS administration decreased from 13.0% in the pre-COVID-19 phase to 1.5% in the COVID-19 phase (<em>P</em>&lt;0.001). An increase in the administration of 20% HAS not backed by agreed clinical evidence followed the increase in new number of COVID-19 cases in the UAE. The current study showed a large proportion of administered HAS, that drastically increased during COVID-19 with lack of clear evidence of its benefit. This pilot study should be followed by refining of the institutional guidelines of HAS use, frequent audits and interactive educational interventions. In turn, the refinement of HAS administration guidelines can help to reduce the unjustified cost of inappropriate HAS use.</p> 2022-08-01T00:00:00+07:00 Copyright (c) 2022 Mohammed Sallam, Johan Snygg https://narraj.org/main/article/view/85 Acceptance and willingness to purchase a hypothetical COVID-19 vaccine in a region under Shariah law: A cross-sectional study in Aceh, Indonesia 2022-07-26T08:31:41+07:00 Muhammad A. Rayhan agam.rayhan97@gmail.com Mudatsir Mudatsir mudatsir@unsyiah.ac.id Nurjannah Nurjannah nurjannah_dr@unsyiah.ac.id Ichsan Ichsan ichsan@unsyiah.ac.id Mehrdad Amir-Behghadami behghadami.m@gmail.com Yousef S. Khader yskhader@just.edu.jo Ai Koyanagi ai.koyanagi@sjd.es Ranjit Sah ranjitsah@iom.edu.np Sandro G. Viveiros-Rosa srosa@inpi.gov.br Mohammed A. Mamun mamun.abdullah@phiju.edu.bd Yohannes K. Lemu yohanneskbd@gmail.com Assarag Bouchra bassarag1@gmail.com Laure SG. Linguissi linguissi@gmail.com Aamer Ikram maahin1@yahoo.com Dina E. Sallam dinaebrahim2008@med.asu.edu.eg Konstantinos Parperis kparpe02@ucy.ac.cy Uwe Wollina uwe.wollina@klinikum-dresden.de Marius Rademaker marius.rademaker@gmail.com Sandro Vento svento@puthisastra.edu.kh Said Usman saidusman@unsyiah.ac.id <div> <div> <p class="NAbstractNEW"><span lang="EN-US">Vaccines are urgently needed to control the coronavirus disease 2019 (COVID-19) pandemic. The aim of this study was to determine the acceptance of and willingness to purchase a hypothetical COVID-19 vaccine in the general population of Aceh, a holistic Shariah law implementation province in Indonesia. An online cross-sectional study was conducted using a quota sampling technique between 1 to 24 September 2021. To determine hypothetical vaccine acceptance, respondents were asked if they were willing to accept vaccines with combinations of either 50% or 95% effectiveness and either 5% or 20% risk of adverse effects. Willingness to purchase was assessed by asking whether the participants would pay for such vaccines at certain price points. Logistic regression analysis was used to assess the associated determinants. Out of </span><span lang="EN-US">377 respondents included in the final analysis, </span><span lang="EN-US">86.5% were willing to accept a COVID-19 vaccine with 95% effectiveness and 5% </span><span lang="EN-US">adverse effects</span><span lang="EN-US">. The acceptance rate dropped to 45.1% if the risk of adverse effects was 20%. Vaccines with 50% effectiveness and 5% adverse effects were acceptable to 42.2% but the acceptance went down to 17.2% if the risk of adverse effects increased to 20%. Multivariate analysis found that men were twice as likely to accept a vaccine with 95% effectiveness and 5% adverse effects compared to females (aOR: 2.01; 95% CI 1.05–3.86). We found that 156/377 (41.3%) of respondents were willing to purchase a COVID-19 vaccine and of these participants 71.1% were willing to pay between Indonesian Rupiah (IDR) 50,000–150,000 (US$ 3.33–10.00). In conclusion, the acceptance rate of a hypothetical COVID-19 vaccine varied based on effectiveness and the risk of adverse effects. </span></p> </div> </div> 2022-08-01T00:00:00+07:00 Copyright (c) 2022 Muhammad A. Rayhan, Mudatsir Mudatsir, Nurjannah Nurjannah, Ichsan Ichsan, Mehrdad Amir-Behghadami, Yousef S. Khader, Ai Koyanagi, Ranjit Sah, Sandro G. Viveiros-Rosa, Mohammed A. Mamun, Yohannes K. Lemu, Assarag Bouchra, Laure SG. Linguissi, Aamer Ikram, Dina E. Sallam, Konstantinos Parperis, Uwe Wollina, Marius Rademaker, Sandro Vento, Said Usman https://narraj.org/main/article/view/84 Pharmaceutical quality evaluation of marketed vildagliptin tablets in Bangladesh based on the United States Pharmacopeia specifications 2022-07-17T18:16:21+07:00 Md. Rabiul Islam robi.ayaan@gmail.com Sohel Daria soheldaria.pharm@gmail.com Arjina A. Ankhi jikoakhi@gmail.com Sharmin Sultana tuly43591@gmail.com Md. Ashrafur Rahman ashrafurrahman82@gmail.com <div> <div> <p class="NAbstractNEW"><span lang="EN-US">Continuous monitoring of pharmaceutical products is vital because it matters to human health. Here we aimed to assess the quality parameters of commercially available vildagliptin tablets in Bangladesh. We tested the tablets for the content uniformity, hardness, friability, disintegration, dissolution, and potency. Then, we fitted the dissolution data with kinetic models to investigate the release pattern of the studied brands. Moreover, we applied a mathematical model-independent approach to compare the dissolution profiles of the brands. The interchangeability was determined using difference and similarity factors. Weight variation, friability, and hardness were between 150.35±1.26 to 230.8±1.98 mg, 0 to 0.88%, and 47.3±5.09 to 108.1±1.92 N, respectively. All tablets disintegrated within 0.54±2.85 to 7.69±2.14 min in distilled water. The potency of tablets in 0.1 N HCl and PBS (pH 6.8) were between 97.67±2.58 to 105±0.95% and 99±4.63 to 105±1.65%, respectively. The drug release (%) in 0.1 N HCl and phosphate-buffered saline (PBS) (pH 6.8) after 60 min were between 99.37±1.80 to 111.09±0.64% and 96.59±3.52 to 109.57±0.53%, respectively. All the brands complied with the United States Pharmacopeia (USP) specification for physicochemical properties. Also, we observed the drug release patterns of vildagliptin tablets matched with different kinetic models. We found only one substitutable brand with the standard product regardless of the dissolution medium. In-vitro chemical equivalence is not always consistent with bioequivalence. Therefore, continuous evaluation of marketed products is essential to ensure the desired quality.</span></p> </div> </div> 2022-08-01T00:00:00+07:00 Copyright (c) 2022 Md. Rabiul Islam, Sohel Daria, Arjina A. Ankhi, Sharmin Sultana, Md. Ashrafur Rahman https://narraj.org/main/article/view/83 Acute severe hepatitis of unknown etiology in children: A mini-review 2022-06-01T09:23:28+07:00 Andri Frediansyah andri.frediansyah@brin.go.id Malik Sallam malik.sallam@ju.edu.jo Amanda Yufika amandayufika@unsyiah.ac.id Khan Sharun sharunkhan@ivri.res.in Muhammad Iqhrammullah m.iqhram@oia.unsyiah.ac.id Deepak Chandran c_deepak@cb.amrita.edu Sukamto S. Mamada sukamto@unhas.ac.id Dina E. Sallam dinaebrahim2008@med.asu.edu.eg Yousef Khader yskhader@just.edu.jo Yohannes K. Lemu yohanneskbd@gmail.com Fauzi Yusuf fauzi.yusuf@unsyiah.ac.id James-Paul Kretchy jkretchy@central.edu.gh Ziad Abdeen zabdeen13@gmail.com J. Smith Torres-Roman jstorresroman@gmail.com Yogesh Acharya dryogeshach19@gmail.com Anastasia Bondarenko bondarenkoanastasia77@gmail.com Aamer Ikram maahin1@yahoo.com Kurnia F. Jamil kurnia_jamil@unsyiah.ac.id Katarzyna Kotfis katarzyna.kotfis@pum.edu.pl Ai Koyanagi ai.koyanagi@sjd.es Lee Smith lee.smith@aru.ac.uk Dewi Megawati amegawati@missouri.edu Marius Rademaker marius.rademaker@gmail.com Talha B. Emran talhabmb@bgctub.ac.bd Ziad A. Memish zmemish@yahoo.com Sandro Vento svento@puthisastra.edu.kh Firzan Nainu firzannainu@unhas.ac.id Harapan Harapan harapan@unsyiah.ac.id <div> <div> <p class="NAbstractNEW"><span lang="EN-US">The emergence of acute, severe non hepA–E hepatitis of unknown etiology (ASHUE) has attracted global concern owing to the very young age of the patients and its unknown etiology. Although this condition has been linked to several possible causes, including viral infection, drugs and/or toxin exposure, the exact cause remains unknown; this makes treatment recommendation very difficult. In this review, we summarize recent updates on the clinical manifestations, complemented with laboratory results, case numbers with the global distribution and other epidemiological characteristics, and the possible etiologies. We also provide the proposed actions that could be undertaken to control and prevent further spread of this hepatitis. Since many etiological and pathological aspects of the acute non hepA–E hepatitis remain unclear, further research is needed to minimize the severe impact of this disease. </span></p> </div> </div> 2022-08-01T00:00:00+07:00 Copyright (c) 2022 Andri Frediansyah, Malik Sallam, Amanda Yufika, Khan Sharun, Muhammad Iqhrammullah, Deepak Chandran, Sukamto S. Mamada, Dina E. Sallam, Yousef Khader, Yohannes K. Lemu, Fauzi Yusuf, James-Paul Kretchy, Ziad Abdeen, J. Smith Torres-Roman, Yogesh Acharya, Anastasia Bondarenko, Aamer Ikram, Kurnia F. Jamil, Katarzyna Kotfis, Ai Koyanagi, Lee Smith, Dewi Megawati, Marius Rademaker, Ziad A. Memish, Sandro Vento, Firzan Nainu, Harapan Harapan https://narraj.org/main/article/view/78 Hepatitis E virus in pigs and the environment: An updated review of public health concerns 2022-06-18T07:30:46+07:00 Tauseef Ahmad hamdardmicrobiologist@gmail.com Hui Jin jinhui_hld@163.com Kuldeep Dhama kdhama@rediffmail.com Mohd. Iqbal Yatoo iqbalyatoo@gmail.com Ruchi Tiwari ruchi.vet@gmail.com Muhammad Bilal bilaluaf@hotmail.com Manish Dhawan dhawanmanish501@gmail.com Talha B. Emran talhabmb@bgctub.ac.bd Jeehan H. Alestad jeehanalostad@gmail.com Hatem M. Alhani hanihm@gmail.com Habib K. BinKhalaf habibk1979@yahoo.com Ali A. Rabaan arabaan@gmail.com <div> <div> <p class="NAbstractNEW"><span lang="EN-US">Hepatitis E virus (HEV) is an important public health problem and is responsible for both acute and chronic viral hepatitis. Public health implications of HEV are derived from its transmission route, either water-borne or food-borne, and its zoonotic potential. Not only in developing countries, but HEV cases are also found in a high number in developed countries. <a name="_Hlk62952015"></a>The spread of HEV to the environment might pollute surface waters, which could act as the source of infection for both humans and animals. Identification of the virus in animal products suggests the circulation of HEV within water and food chains. High seroprevalence and circulation of HEV in livestock, in particular pigs, as well as in environmental samples warrants further investigation into pig markets. HEV virulence in different environments and meat supply chains could shed light on the possible sources of infection in humans and the degree of occupational risk. The purpose of this review is to discuss HEV infections with an emphasis on livestock- and environment-related risk factors, and food-borne, water-borne, and zoonotic transmissions.</span></p> </div> </div> 2022-08-01T00:00:00+07:00 Copyright (c) 2022 Tauseef Ahmad, Hui Jin, Kuldeep Dhama, Mohd. Iqbal Yatoo, Ruchi Tiwari, Muhammad Bilal, Manish Dhawan, Talha B. Emran, Jeehan H. Alestad, Hatem M. Alhani, Habib K. BinKhalaf, Ali A. Rabaan https://narraj.org/main/article/view/80 Challenges on tuberculosis care in health care facilities during COVID-19 pandemic: Indonesian perspective 2022-06-01T09:35:32+07:00 Wira Winardi wira.winardi@unsyiah.ac.id Hendra Wahyuni hendrawms@unimal.ac.id Moulid Hidayat moulid.hidayat.md@unram.ac.id Aditya Wirawan wirawan_aditya84@yahoo.com Fariz Nurwidya fariz.nurwidya@ui.ac.id Mohammad N. Uddin n-uddin@juntendo.ac.jp Mohamad Yusup rinduazmy@gmail.com <div> <div> <p class="NAbstractNEW"><span lang="EN-US">Indonesia is among the top three countries globally with the highest tuberculosis burden. During the past decades, Indonesian health authorities have struggled to improve tuberculosis care quality in health care facilities by optimizing the regulation and strengthening the private sector contributions. The coronavirus disease 2019 (COVID-19) pandemic has hardly affected the Indonesian health care system, including the National Tuberculosis Control Program. While the end of the COVID-19 pandemic in Indonesia is uncertain, the measure to control tuberculosis must not be weakened. Early identification and measurement of the problem size are essential to decide the most appropriate approach to maintain the sustainability of National Tuberculosis Control Program, particularly in health care facilities during the COVID-19 pandemic. This article points out the possible threats to the sustainability of TB care in Indonesia during the COVID-19 pandemic, including some approaches to overcome those problems. </span></p> </div> </div> 2022-08-01T00:00:00+07:00 Copyright (c) 2022 Wira Winardi, Hendra Wahyuni, Moulid Hidayat, Aditya Wirawan, Mohammad N. Uddin, Mohamad Yusup